Efficacy analysis of different FLT3 inhibitors in patients with relapsed/refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome

Several FLT3 inhibitors(i) are available to treat relapsed/refractory (R/R) FLT3‐internal tandem duplicated acute myeloid leukemia (AML). This study analyzes the efficacies of various FLT3i (types 1 and 2) tested in clinical trials in treating R/R AML and high‐risk myelodysplastic syndromes (HR‐MDS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Swaminathan, Mahesh, Aly, Mai M., Khan, Abdul Moiz, Share, Bayan Al, Dhillon, Vikram, Lalo, Enxhi, Ramos, Harry, Akers, Katherine G., Kim, Seongho, Balasubramanian, Suresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematologic Malignancy ‐ Myeloid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928788/
https://www.ncbi.nlm.nih.gov/pubmed/36819163
http://dx.doi.org/10.1002/jha2.616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928788/
https://www.ncbi.nlm.nih.gov/pubmed/36819163
http://dx.doi.org/10.1002/jha2.616

Ejemplares similares